Transdiagnostic treatment of emotional disorders for women with multiple sclerosis: a randomized controlled trial

Abstract Background Multiple sclerosis (MS) is a chronic, unpredictable, neurodegenerative disease, significantly associated with psychological, behavioral, cognitive, and emotional consequences. MS is more common in females than males and frequently affects women during their reproductive years. De...

Full description

Saved in:
Bibliographic Details
Main Authors: Nabi Nazari (Author), Akram Aligholipour (Author), Masoud Sadeghi (Author)
Format: Book
Published: BMC, 2020-10-01T00:00:00Z.
Subjects:
Online Access:Connect to this object online.
Tags: Add Tag
No Tags, Be the first to tag this record!

MARC

LEADER 00000 am a22000003u 4500
001 doaj_3d1ddb7eb35543e685ce90ad9c9cde1c
042 |a dc 
100 1 0 |a Nabi Nazari  |e author 
700 1 0 |a Akram Aligholipour  |e author 
700 1 0 |a Masoud Sadeghi  |e author 
245 0 0 |a Transdiagnostic treatment of emotional disorders for women with multiple sclerosis: a randomized controlled trial 
260 |b BMC,   |c 2020-10-01T00:00:00Z. 
500 |a 10.1186/s12905-020-01109-z 
500 |a 1472-6874 
520 |a Abstract Background Multiple sclerosis (MS) is a chronic, unpredictable, neurodegenerative disease, significantly associated with psychological, behavioral, cognitive, and emotional consequences. MS is more common in females than males and frequently affects women during their reproductive years. Despite the frequent mental disorders, comorbidities, and emotional problems in People with MS (PwMS), these conditions are too often underdiagnosed and undertreated. Objective This study aimed to examine the efficacy of a group format of the Unified Protocol (UP) for the Transdiagnostic treatment of depression and anxiety disorders in females with MS. Methods In the present study, Sixty-four adult females diagnosed with MS were randomized to either the UP (n = 32) or treatment-as-usual conditions. The assessment protocol included semi-structured clinical interviews and self-reports evaluating diagnostic criteria, depression, anxiety and worry symptoms, emotional regulation, and affectivity. Results Repeated measure analysis of variance (ANOVA) revealed that the UP significantly improved depression scores [Cohen's d = − 2.11, 95% CI (− 2.72, − 1.50)], anxiety scores [Cohen's d = − 3.34, 95% CI (− 4.01, − 2.58)], positive and negative affect scale (PANAS)-positive affect scores [Cohen's d = 1.46, 95% CI (1.46, 2.01)], PANAS-negative affect scores [Coen's d = − 2.21, 95% CI (− 2.84, − 1.60)], difficulties emotion regulation scale scores [Cohen's d = 1.40, 95% CI (− 0.87, − 0.03)], and Worry scale scores [Cohen's d = − 0.45, 95% CI (− 0.95, − 0.04)] at the end of treatment relative to compared to the control condition. Also, treatment gains were maintained at the three-month follow-up (p < 0.001). Conclusion The findings provide the support that the UP could be an additional efficient psychological treatment for females with MS. ISRCTN Number: ISRCTN95459505. 
546 |a EN 
690 |a Unified protocol 
690 |a Emotion regulation 
690 |a Comorbidity 
690 |a Depression 
690 |a Anxiety 
690 |a Gynecology and obstetrics 
690 |a RG1-991 
690 |a Public aspects of medicine 
690 |a RA1-1270 
655 7 |a article  |2 local 
786 0 |n BMC Women's Health, Vol 20, Iss 1, Pp 1-11 (2020) 
787 0 |n http://link.springer.com/article/10.1186/s12905-020-01109-z 
787 0 |n https://doaj.org/toc/1472-6874 
856 4 1 |u https://doaj.org/article/3d1ddb7eb35543e685ce90ad9c9cde1c  |z Connect to this object online.